Toxicity Assessment of Resveratrol Liposomes-in-Hydrogel Delivery System by EpiVaginal Tissue Model
The natural polyphenol resveratrol (RES) has shown great potential as an antimicrobial, including against microbes associated with vaginal infections. To fully exploit the activities of RES, an all-natural ingredients formulation for RES delivery at vaginal site has been developed, namely liposomes...
Gespeichert in:
Veröffentlicht in: | PHARMACEUTICS 2022-06, Vol.14 (6), p.1295 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | The natural polyphenol resveratrol (RES) has shown great potential as an antimicrobial,
including against microbes associated with vaginal infections. To fully exploit the activities of RES,
an all-natural ingredients formulation for RES delivery at vaginal site has been developed, namely
liposomes loaded with RES, incorporated into a chitosan hydrogel as secondary vehicle. Although
considered non-toxic and safe on their own, the compatibility of the final formulation must be evaluated for its biocompatibility and non-irritancy to the vaginal mucosa. As a preclinical safety assessment, the impact of RES formulation on the tissue viability, the effect on barrier function and
cell monolayer integrity, and cytotoxicity were evaluated using the cell-based vaginal tissue model,
the EpiVaginal™ tissue. RES liposomes-in-hydrogel formulations neither affected the mitochondrial activity, nor the integrity of the cell monolayer in RES concentration up to 60 µg/mL. Moreover, the barrier function was maintained to a greater extent by RES in formulation, emphasizing the
benefits of the delivery system. Additionally, none of the tested formulations expressed an increase
in lactate dehydrogenase activity compared to the non-treated tissues. The evaluation of the RES
delivery system suggests that it is non-irritant and biocompatible with vaginal tissue in vitro in the
RES concentrations considered as therapeutic. |
---|---|
ISSN: | 1999-4923 1999-4923 |
DOI: | 10.3390/pharmaceutics14061295 |